Events & Webinars
Podcasts
Resources
Learning Zone
Products
Service Optimization & Formularies
Cardiovascular
Women's Health
Nephrology
Oncology
Respiratory
Bayer for Professionals
Your Resource Portal
Register | Log In
PP-PF-ONC-GB-0410 | April 2024
Explore Oncology Events & Webinars
Prostate Cancer Events & Webinars
View more
BOPA 2021
NUBEQA®▼ (darolutamide)
NUBEQA GB Prescribing Information
NUBEQA NI Prescribing Information
PP-NUB-GB-1299, February 2024
BAUS 2022: Navigating treatment decisions in nmCRPC patients
NUBEQA®▼ (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-1298, February 2024
The evolving nmCRPC treatment landscape
NUBEQA®▼ (darolutamide)
NUBEQA GB Prescribing Information
NUBEQA NI Prescribing Information
PP-NUB-GB-1320, February 2024
BAUS 2023: When and how to treat prostate cancer?
NUBEQA®▼ (darolutamide)
NUBEQA Prescribing Information
PP-NUB-GB-1300, February 2024
Tyrosine Kinase Inhibitor (TKI) Events & Webinars
View more
UKOF 2023 Symposium
Stivarga® (regorafenib)
Stivarga Prescribing Information
PP-STI-GB-0274, February 2024
The management and treatment of patients
Nexavar® (sorafenib) | Stivarga® (regorafenib)
Nexavar Prescribing Information
Stivarga Prescribing Information
PP-NEX-GB-0212, February 2024
Bayer Oncology HCC Clinical Expert Series
Nexavar® (sorafenib) | Stivarga® (regorafenib)
Nexavar Prescribing Information
Stivarga Prescribing Information
PP-NEX-GB-0218, February 2024
Ask the experts: Three key questions on mCRC
Stivarga® (regorafenib)
Stivarga Prescribing Information
PP-STI-GB-0205, February 2024
